ATE542570T1 - Verwendung kardiotonischer steroiden als na/k- atpase liganden zur hautbehandlung - Google Patents
Verwendung kardiotonischer steroiden als na/k- atpase liganden zur hautbehandlungInfo
- Publication number
- ATE542570T1 ATE542570T1 AT07762999T AT07762999T ATE542570T1 AT E542570 T1 ATE542570 T1 AT E542570T1 AT 07762999 T AT07762999 T AT 07762999T AT 07762999 T AT07762999 T AT 07762999T AT E542570 T1 ATE542570 T1 AT E542570T1
- Authority
- AT
- Austria
- Prior art keywords
- skin treatment
- cardiotonic steroids
- atpase
- ligands
- atpase ligands
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76378306P | 2006-01-31 | 2006-01-31 | |
PCT/US2007/002365 WO2007089688A2 (en) | 2006-01-31 | 2007-01-30 | Na/k-atpase ligand |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE542570T1 true ATE542570T1 (de) | 2012-02-15 |
Family
ID=38327955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07762999T ATE542570T1 (de) | 2006-01-31 | 2007-01-30 | Verwendung kardiotonischer steroiden als na/k- atpase liganden zur hautbehandlung |
Country Status (7)
Country | Link |
---|---|
US (3) | US8906891B2 (de) |
EP (1) | EP1993672B1 (de) |
JP (1) | JP5484735B2 (de) |
CN (1) | CN101374571B (de) |
AT (1) | ATE542570T1 (de) |
CA (1) | CA2641303C (de) |
WO (1) | WO2007089688A2 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1993672B1 (de) | 2006-01-31 | 2012-01-25 | The University of Toledo | Verwendung kardiotonischer Steroiden als Na/K-ATPase liganden zur Hautbehandlung |
EP2086528B1 (de) | 2006-10-31 | 2016-10-26 | University Of Toledo | Na+/k+-atpase-spezifische peptidhemmer von src und kinasen der src-familie |
CN102573469B (zh) | 2009-09-16 | 2015-02-25 | 托莱多大学 | Na/K-ATP酶配体、毒毛花苷G拮抗剂及其测试方法和用途 |
CN102811729B (zh) * | 2010-01-13 | 2015-02-11 | 托莱多大学 | 钠/钾三磷酸腺苷酶及src相关的材料和方法 |
ES2970792T3 (es) * | 2019-10-09 | 2024-05-30 | Windtree Therapeutics Inc | Derivados de androstano con actividad como estimuladores puros o predominantemente puros de SERCA2A para el tratamiento de la insuficiencia cardíaca |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2698822A (en) | 1951-04-28 | 1955-01-04 | Fougera & Co Inc E | Cardiac glycoside buccal composition |
US3122475A (en) | 1960-02-25 | 1964-02-25 | Schaeppi Ag Dr | Circulatory adjuvant shell elements for cardiac glycoside suppository cores |
US3687944A (en) | 1970-05-08 | 1972-08-29 | George R Pettit | Process for the preparation of bufalin and related compounds |
SE426548B (sv) * | 1978-12-05 | 1983-01-31 | Haessle Ab | Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer |
US5153178A (en) * | 1982-05-14 | 1992-10-06 | Maroko Peter R | Compositions and method of treatment for improving circulatory performance |
EP0817636B1 (de) | 1995-02-21 | 2003-01-15 | Unigen Pharmaceuticals, Inc. | Aus aloe barbadensis isoliertes cinnamoyl-c-glykosid chromon |
US5977077A (en) | 1995-08-28 | 1999-11-02 | Interlab Corporation | Xanthone analogs for the treatment of infectious diseases |
US5891855A (en) | 1996-02-12 | 1999-04-06 | The Scripps Research Institute | Inhibitors of leaderless protein export |
US6531165B2 (en) * | 1997-01-17 | 2003-03-11 | Shiseido Company, Ltd. | Collagen production promoter composition |
US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
KR100342440B1 (ko) | 1999-12-24 | 2002-07-04 | 손 경 식 | 섬수 정제엑스를 이용한 성신경과민증 예방 및 치료용 의약조성물 및 그 제조방법 |
US20030180379A1 (en) | 2000-07-27 | 2003-09-25 | Burrell Robert E. | Solutions and aerosols of metal-containing compounds |
WO2002014343A1 (en) * | 2000-08-17 | 2002-02-21 | Terness, Peter | Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents |
CA2446864C (en) | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
AU2003295423A1 (en) | 2002-11-07 | 2004-06-03 | University Of Medicine And Dentistry Of New Jersey | Novel pharmacophore for the discovery and testing of na, k-atpase inhibitor compositions and methods for their use in treating cardiovascular diseases and conditions |
US20050026849A1 (en) * | 2003-03-28 | 2005-02-03 | Singh Chandra U. | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases |
CA2559458A1 (en) | 2004-03-19 | 2005-10-06 | Xiu-Min Li | Herbal therapy for the treatment of food allergy |
FR2871060B1 (fr) * | 2004-06-08 | 2008-07-11 | Ajinomoto Kk | Agent suppresseur pour l'inflammation et procede l'utilisant |
US20060004002A1 (en) | 2004-07-02 | 2006-01-05 | Thomas Thrash | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors |
US20060135468A1 (en) | 2004-09-02 | 2006-06-22 | Bionaut Pharmaceuticals, Inc. | Treatment of refractory cancers using NA+/K+ ATPase inhibitors |
US20060205679A1 (en) * | 2004-10-22 | 2006-09-14 | Azaya Therapeutics, Inc. | Topical and oral formulations of cardiac glycosides for treating skin diseases |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
US20070092970A1 (en) | 2005-10-25 | 2007-04-26 | Liang Dong C | High-throughput screening assay for Na, K-ATPase using atomic absorption spectroscopy |
EP1993672B1 (de) | 2006-01-31 | 2012-01-25 | The University of Toledo | Verwendung kardiotonischer Steroiden als Na/K-ATPase liganden zur Hautbehandlung |
CA2682385A1 (en) | 2006-05-09 | 2007-11-15 | Jr. Roland Valdes | Treating cancer with cardiac glycosides |
US7858126B2 (en) | 2006-08-31 | 2010-12-28 | Trinity Laboratories Inc. | Derivatives of sandalwood oil and santalols for treating cold sores and herpes |
EP2086528B1 (de) | 2006-10-31 | 2016-10-26 | University Of Toledo | Na+/k+-atpase-spezifische peptidhemmer von src und kinasen der src-familie |
EP2346518B1 (de) | 2008-10-14 | 2020-09-02 | Nerium Biotechnology, Inc. | Verfahren zur extraktion von herzglycosiden aus nerium oleader und zusammensetzungen |
EP2361097A4 (de) | 2008-12-12 | 2012-04-25 | Univ Toledo | Scr-hemmer mit aus na/k-atpase abgeleiteten peptiden sowie ouabain-antagonisten und anwendungen davon |
CN102573469B (zh) | 2009-09-16 | 2015-02-25 | 托莱多大学 | Na/K-ATP酶配体、毒毛花苷G拮抗剂及其测试方法和用途 |
CN102811729B (zh) | 2010-01-13 | 2015-02-11 | 托莱多大学 | 钠/钾三磷酸腺苷酶及src相关的材料和方法 |
-
2007
- 2007-01-30 EP EP20070762999 patent/EP1993672B1/de not_active Not-in-force
- 2007-01-30 CN CN2007800038628A patent/CN101374571B/zh not_active Expired - Fee Related
- 2007-01-30 US US12/087,976 patent/US8906891B2/en active Active
- 2007-01-30 WO PCT/US2007/002365 patent/WO2007089688A2/en active Application Filing
- 2007-01-30 CA CA 2641303 patent/CA2641303C/en not_active Expired - Fee Related
- 2007-01-30 AT AT07762999T patent/ATE542570T1/de active
- 2007-01-30 JP JP2008553283A patent/JP5484735B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-25 US US13/850,218 patent/US9072751B2/en active Active
-
2015
- 2015-07-06 US US14/792,375 patent/US9492463B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2009525334A (ja) | 2009-07-09 |
WO2007089688A2 (en) | 2007-08-09 |
US20090226513A1 (en) | 2009-09-10 |
US20150342966A1 (en) | 2015-12-03 |
EP1993672A2 (de) | 2008-11-26 |
US8906891B2 (en) | 2014-12-09 |
US9072751B2 (en) | 2015-07-07 |
US9492463B2 (en) | 2016-11-15 |
JP5484735B2 (ja) | 2014-05-07 |
EP1993672B1 (de) | 2012-01-25 |
CA2641303C (en) | 2013-05-14 |
US20140128356A1 (en) | 2014-05-08 |
EP1993672A4 (de) | 2009-09-16 |
WO2007089688A3 (en) | 2008-03-06 |
CN101374571A (zh) | 2009-02-25 |
CN101374571B (zh) | 2013-07-17 |
CA2641303A1 (en) | 2007-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500045A1 (en) | Compositions and methods for treating and diagnosing asthma | |
MY159815A (en) | Notch1 receptor binding agents and methods of use thereof | |
MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
GB2467467B (en) | TAZ/WWTR1 for diagnosis and treatment of cancer | |
MX2009012722A (es) | Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama. | |
WO2010085542A3 (en) | Biomarkers related to age-related macular degeneration (amd) | |
MX368513B (es) | Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón. | |
PH12014502507A1 (en) | Anti-angiogenesis therapy for the treatment of breast cancer | |
WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
EP3683320A3 (de) | Mirna-fingerabdruck in der diagnose von lungenkrebs | |
WO2010091049A3 (en) | Diagnosis and treatment of cancer | |
NZ584787A (en) | Inhibition of angiogenesis with a Bv8 antagonist | |
WO2012045905A3 (es) | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama | |
MX2015004610A (es) | Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf. | |
TR201907261T4 (tr) | DKK-1 antikorları. | |
WO2009015050A3 (en) | Gene expression profile for predicting ovarian cancer patient survival | |
PH12016500047A1 (en) | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211-seqid2) | |
ATE542570T1 (de) | Verwendung kardiotonischer steroiden als na/k- atpase liganden zur hautbehandlung | |
MX2007010484A (es) | Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. | |
WO2011106785A3 (en) | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith | |
WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
ATE487947T1 (de) | Verfahren zur diagnose und behandlung auf nr2- peptiden beruhender zerebrovaskulärer ereignisse | |
WO2009091230A3 (ko) | 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법 | |
GB2465907A (en) | VHZ for diagnosis and treatment of cancer | |
EA201490201A1 (ru) | Выявление экспрессии гена prame при раковом заболевании |